Hikma and Celltrion Expand Partnership to Boost Biosimilar Access in MENA

Hikma Pharmaceuticals PLC and South Korea’s Celltrion Inc. have signed new exclusive licensing agreements to introduce six biosimilar treatments across the Middle East and North Africa (MENA). The collaboration aims to enhance access to affordable biologics in therapeutic areas including oncology, immune diseases, ophthalmology, and skeletal-related disorders.

Advancing Affordable Healthcare Through Innovation

Under the agreements, Celltrion will oversee development, manufacturing, and supply, while Hikma will retain exclusive commercialization rights across all MENA markets. By expanding their biosimilar portfolio, Hikma is addressing treatment gaps and reducing healthcare costs, ensuring wider patient access to life-saving and life-enhancing therapies across the region.

Strengthening Hikma’s Biotech Leadership in MENA

This expansion solidifies Hikma’s leadership in biosimilars and supports its broader biotech strategy to improve hospital care standards and patient outcomes. “We are proud to expand our partnership with Celltrion, reinforcing our shared commitment to improving access to high-quality biosimilar treatments,” said Mazen Darwazah, Executive Vice Chairman and President of MENA at Hikma.